Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

Cell-based therapeutic strategies for multiple sclerosis.

Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis.

Brain. 2017 Jul 21. doi: 10.1093/brain/awx154. [Epub ahead of print]

PMID:
29053779
2.

Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation.

Bhargava P, Fitzgerald KC, Calabresi PA, Mowry EM.

JCI Insight. 2017 Oct 5;2(19). pii: 95302. doi: 10.1172/jci.insight.95302. [Epub ahead of print]

3.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2017 Aug 1:1352458517723718. doi: 10.1177/1352458517723718. [Epub ahead of print]

PMID:
28799444
4.

Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.

Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH; 2016 ECTRIMS Focused Workshop Group.

Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847. [Epub ahead of print]

PMID:
28671487
5.

Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.

Foley RW, Tagg NT, Schindler MK, Fenton KM, Reich DS, Cortese I, Mowry EM.

Mult Scler. 2017 Sep;23(10):1424-1427. doi: 10.1177/1352458517702533. Epub 2017 Jun 22.

PMID:
28639536
6.

Follow-Up of Emergency Department MRI Scans Suggesting New Diagnosis of CNS Demyelination.

Pakpoor J, Saylor D, Izbudak I, Liu L, Mowry EM, Probasco J, Yousem DM.

AJR Am J Roentgenol. 2017 Jul;209(1):171-175. doi: 10.2214/AJR.16.17279. Epub 2017 May 2.

PMID:
28463541
7.

PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.

Mowry EM, McArthur JC.

Neurology. 2017 Mar 21;88(12):1110-1111. doi: 10.1212/WNL.0000000000003749. Epub 2017 Feb 22. No abstract available.

PMID:
28228562
8.

Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.

Motl RW, Mowry EM, Ehde DM, LaRocca NG, Smith KE, Costello K, Shinto L, Ng AV, Sullivan AB, Giesser B, McCully KK, Fernhall B, Bishop M, Plow M, Casaccia P, Chiaravalloti ND.

Mult Scler. 2017 Jan 1:1352458516687404. doi: 10.1177/1352458516687404. [Epub ahead of print]

PMID:
28080254
9.

Neuromyelitis optica unmasked by a spinal dural arteriovenous fistula.

Freund B, Mowry EM, McR, Levy M, Newsome SD.

J Neuroimmunol. 2016 Nov 15;300:18-20. doi: 10.1016/j.jneuroim.2016.10.005. Epub 2016 Oct 12.

PMID:
27806871
10.

Environmental and genetic factors in pediatric inflammatory demyelinating diseases.

Waubant E, Ponsonby AL, Pugliatti M, Hanwell H, Mowry EM, Hintzen RQ.

Neurology. 2016 Aug 30;87(9 Suppl 2):S20-7. doi: 10.1212/WNL.0000000000003029. Review.

PMID:
27572857
11.

Long-term evolution of multiple sclerosis disability in the treatment era.

University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL.

Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.

12.

Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - Commentary.

Mowry EM.

Mult Scler. 2016 Sep;22(10):1263-5. doi: 10.1177/1352458516660206. Epub 2016 Jul 21. No abstract available.

PMID:
27444561
13.

Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.

Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Ávila AL, Le DT, Lipson EJ, Probasco JC, Mowry EM.

JAMA Neurol. 2016 Aug 1;73(8):928-33. doi: 10.1001/jamaneurol.2016.1399.

PMID:
27271951
14.

Emerging Concepts on the Gut Microbiome and Multiple Sclerosis.

Glenn JD, Mowry EM.

J Interferon Cytokine Res. 2016 Jun;36(6):347-57. doi: 10.1089/jir.2015.0177. Epub 2016 May 4.

15.

Genetic predictors of relapse rate in pediatric MS.

Graves JS, Barcellos LF, Shao X, Noble J, Mowry EM, Quach H, Belman A, Casper TC, Krupp LB, Waubant E; U.S. Network of Pediatric MS Centers.

Mult Scler. 2016 Oct;22(12):1528-1535. Epub 2016 Jan 14.

16.

Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.

Sotirchos ES, Bhargava P, Eckstein C, Van Haren K, Baynes M, Ntranos A, Gocke A, Steinman L, Mowry EM, Calabresi PA.

Neurology. 2016 Jan 26;86(4):382-90. doi: 10.1212/WNL.0000000000002316. Epub 2015 Dec 30.

17.

Evidence for the Importance of Vitamin D Status in Neurologic Conditions.

Yeshokumar AK, Saylor D, Kornberg MD, Mowry EM.

Curr Treat Options Neurol. 2015 Dec;17(12):51. doi: 10.1007/s11940-015-0380-3.

PMID:
26538263
18.

Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls.

Bhargava P, Steele SU, Waubant E, Revirajan NR, Marcus J, Dembele M, Cassard SD, Hollis BW, Crainiceanu C, Mowry EM.

Mult Scler. 2016 May;22(6):753-60. doi: 10.1177/1352458515600248. Epub 2015 Aug 18.

19.

Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis.

Maghzi AH, Revirajan N, Julian LJ, Spain R, Mowry EM, Liu S, Jin C, Green AJ, McCulloch CE, Pelletier D, Waubant E.

Mult Scler Relat Disord. 2014 Nov;3(6):720-7. doi: 10.1016/j.msard.2014.07.003. Epub 2014 Jul 23.

PMID:
25891551
20.

Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.

Graves J, Vinayagasundaram U, Mowry EM, Matthews IR, Marino JA, Cheng J, Waubant E.

Mult Scler Relat Disord. 2014 Mar;3(2):244-52. doi: 10.1016/j.msard.2013.10.003. Epub 2013 Oct 25.

PMID:
25878012

Supplemental Content

Loading ...
Support Center